Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Risperidone controlled release - Bausch Health Companies

Next Previous
Drug Profile

Risperidone controlled release - Bausch Health Companies

Alternative Names: Relday; Risperidone sustained release; SABER™ risperidone; ZX-003

Latest Information Update: 17 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DURECT Corporation
  • Developer Bausch Health Companies
  • Class Antidepressants; Antineoplastics; Antipsychotics; Behavioural disorder therapies; Fluorinated hydrocarbons; Isoxazoles; Mood stabilisers; Piperidines; Pyrimidinones; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 5-HT2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Bipolar disorders; Schizophrenia

Most Recent Events

  • 11 Sep 2025 DURECT Corporation has been acquired and merged into Bausch Health Companies
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Schizophrenia in USA (SC, Controlled release)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Bipolar-disorders in USA (SC, Controlled release)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top